STUHEC, Matej, M. HAHN, Ivana TAŠKOVÁ, I. BAYRAKTAR, I. FITZGERALD, L. MOLITSCHNIG, A. TATAREVIC, N. LINDNER, L. AGNOLETTO and F. DA COSTA. Clinical pharmacy services in mental health in Europe: a commentary paper of the European Society of Clinical Pharmacy Special Interest Group on Mental Health. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY. NETHERLANDS: SPRINGER, 2023, vol. 45, No 5, p. 1286-1292. ISSN 2210-7703. Available from: https://dx.doi.org/10.1007/s11096-023-01643-4.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Clinical pharmacy services in mental health in Europe: a commentary paper of the European Society of Clinical Pharmacy Special Interest Group on Mental Health
Authors STUHEC, Matej (705 Slovenia), M. HAHN (276 Germany), Ivana TAŠKOVÁ (203 Czech Republic, belonging to the institution), I. BAYRAKTAR (792 Turkey), I. FITZGERALD (372 Ireland), L. MOLITSCHNIG (40 Austria), A. TATAREVIC (191 Croatia), N. LINDNER (40 Austria), L. AGNOLETTO (40 Austria) and F. DA COSTA (620 Portugal).
Edition INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, NETHERLANDS, SPRINGER, 2023, 2210-7703.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher Netherlands
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.400 in 2022
RIV identification code RIV/00216224:14160/23:00133605
Organization unit Faculty of Pharmacy
Doi http://dx.doi.org/10.1007/s11096-023-01643-4
UT WoS 001073897200001
Keywords in English Clinical pharmacist interventions; Clinical pharmacy in mental health; European society of clinical pharmacy; Mental illnesses and pharmacy; Pharmaceutical services in mental health; Polypharmacy and clinical pharmacy; Psychotropics and clinical pharmacy
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Daniela Černá, učo 489184. Changed: 28/2/2024 07:22.
Abstract
A large proportion of the world's disease burden is attributable to mental illnesses. Although effective interventions are available, many patients still have limited access to evidence-based treatments. Aside from access, treatment gaps, including inappropriate medication selection and monitoring, are also routinely recognised. Mental health clinical pharmacists can help address these gaps and enable patients to receive optimised pharmaceutical care, particularly appropriate medication selection and monitoring. The European Society of Clinical Pharmacy (ESCP) Special Interest Group on Mental Health was established to improve standardised service provision in mental health settings across Europe. The Special Interest Group identified significant barriers (predominantly associated with reimbursement and position within the multidisciplinary team) to effective pharmaceutical care amongst those with mental illnesses. This commentary presents recommendations to address these gaps through improved mental health clinical pharmacy service provision.
PrintDisplayed: 6/7/2024 07:17